科兴制药
(688136)
| 流通市值：33.76亿 | | | 总市值：33.76亿 |
| 流通股本：1.99亿 | | | 总股本：1.99亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 360,663,523.23 | 1,259,035,602.11 | 968,997,954.79 | 648,964,150.78 |
| 营业收入 | 360,663,523.23 | 1,259,035,602.11 | 968,997,954.79 | 648,964,150.78 |
| 二、营业总成本 | 343,201,937.56 | 1,531,478,581.93 | 1,071,969,453.6 | 750,089,977.69 |
| 营业成本 | 98,683,347.49 | 367,752,053.98 | 276,051,998.18 | 182,515,040.15 |
| 税金及附加 | 3,194,566.5 | 11,638,059.33 | 8,183,586.52 | 5,239,017.15 |
| 销售费用 | 177,447,776.64 | 689,290,396.42 | 536,590,616.5 | 384,095,925.79 |
| 管理费用 | 19,722,952.69 | 86,816,469.86 | 59,881,108.43 | 40,434,544 |
| 研发费用 | 35,207,355.05 | 344,796,850.58 | 168,365,540.44 | 124,315,452.96 |
| 财务费用 | 8,945,939.19 | 31,184,751.76 | 22,896,603.53 | 13,489,997.64 |
| 其中:利息费用 | 10,039,548.63 | 39,134,557.73 | 29,922,552.81 | 19,582,213.75 |
| 其中:利息收入 | 1,121,013.07 | 6,643,109.76 | 5,629,382.27 | 3,798,783.94 |
| 加:公允价值变动收益 | - | 238,629.61 | 20,923,157.5 | 20,923,157.5 |
| 加:投资收益 | 1,786,622.55 | 6,527,800.17 | 4,385,023.97 | 2,348,916.11 |
| 资产处置收益 | 100,857.6 | 281,292.19 | 37,067.15 | - |
| 资产减值损失(新) | -1,103,237.58 | -2,561,695.3 | -2,088,945.59 | -798,339.02 |
| 信用减值损失(新) | -3,164,076.95 | 2,928,041.08 | 1,006,612.36 | 804,614.99 |
| 其他收益 | 760,096.42 | 8,797,185.18 | 6,192,074.16 | 4,835,962.84 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 15,841,847.71 | -256,231,726.89 | -72,516,509.26 | -73,011,514.49 |
| 加:营业外收入 | 130,823.78 | 758,828.9 | 2,305.44 | 2,305.29 |
| 减:营业外支出 | 37,670.02 | 4,597,069.12 | 2,350,435.85 | 346,774.09 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 15,935,001.47 | -260,069,967.11 | -74,864,639.67 | -73,355,983.29 |
| 减:所得税费用 | 4,446,744.19 | -64,583,444.87 | -16,736,588.68 | -23,433,461.92 |
| 六、净利润 | 11,488,257.28 | -195,486,522.24 | -58,128,050.99 | -49,922,521.37 |
| 持续经营净利润 | 11,488,257.28 | -195,486,522.24 | -58,128,050.99 | -49,922,521.37 |
| 归属于母公司股东的净利润 | 12,403,443.45 | -190,290,325.13 | -54,314,791.05 | -47,561,505.48 |
| 少数股东损益 | -915,186.17 | -5,196,197.11 | -3,813,259.94 | -2,361,015.89 |
| (一)基本每股收益 | 0.06 | -0.96 | -0.27 | -0.24 |
| (二)稀释每股收益 | 0.06 | -0.96 | -0.27 | -0.24 |
| 八、其他综合收益 | 386,804.06 | -6,259.8 | - | - |
| 归属于母公司股东的其他综合收益 | 386,804.06 | -6,259.8 | - | - |
| 九、综合收益总额 | 11,875,061.34 | -195,492,782.04 | -58,128,050.99 | -49,922,521.37 |
| 归属于母公司股东的综合收益总额 | 12,790,247.51 | -190,296,584.93 | -54,314,791.05 | -47,561,505.48 |
| 归属于少数股东的综合收益总额 | -915,186.17 | -5,196,197.11 | -3,813,259.94 | -2,361,015.89 |
| 公告日期 | 2024-04-27 | 2024-04-27 | 2023-10-28 | 2023-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |